$35.00
Manufacturer: Ukraine
Chronic paranoid and hallucinatory-paranoid states, states of psychomotor agitation in patients with schizophrenia (hallucinatory-delusional, hebephrenic, catatonic syndromes), alcoholic psychosis, manic arousal in patients with manic-depressive psychosis, mental disorders in patients with epilepsy, agitated depression in patients with presenile, manic-depressive psychoses, as well as other diseases accompanied by excitement, tension. Neurotic diseases, accompanied by an increase in muscle tone. Persistent pain, including causalgia (in combination with analgesics), persistent sleep disturbances (in combination with hypnotics and tranquilizers). Meniere’s disease, vomiting in pregnancy, treatment and prevention of vomiting in the treatment of anticancer drugs and radiation therapy. Dermatous itching. As part of lytic mixtures in anesthesiology.
Description
Ingredients
active ingredients about: chlorpromazine;
1 ml of solution contains chlorpromazine hydrochloride 25 mg;
excipients a: anhydrous sodium sulfite (E 221), sodium metabisulfite (E 223), ascorbic acid, sodium chloride, water for injection.
Dosage form
Injection.
Basic physical and chemical properties : transparent colorless or yellowish, or greenish-yellow liquid.
Pharmacotherapeutic group
Antipsychotic drugs. Phenothiazine derivatives with aliphatic structure.
ATX code N05A A01.
Pharmacodynamics
A neuroleptic of the group of phenothiazine derivatives. Shows a pronounced antipsychotic, sedative and antiemetic effect. It weakens or completely eliminates delusions and hallucinations, stops psychomotor agitation, reduces affective reactions, anxiety, anxiety, and reduces motor activity. The mechanism of antipsychotic action is associated with the blockade of postsynaptic dopaminergic receptors in the mesolimbic structures of the brain. It also has a blocking effect on
α-adrenergic receptors and inhibits the release of pituitary and hypothalamic hormones. However, blockade of dopamine receptors increases the secretion of prolactin by the pituitary gland. The antiemetic effect is due to inhibition or blockade of dopamine D2 receptors in the chemoreceptor trigger zone of the cerebellum, peripherally – blockade of the vagus nerve in the digestive system. The sedative effect is due to the blockade of central adrenergic receptors. Shows a moderate or weak effect on extrapyramidal structures.
Indications
Chronic paranoid and hallucinatory-paranoid states, states of psychomotor agitation in patients with schizophrenia (hallucinatory-delusional, hebephrenic, catatonic syndromes), alcoholic psychosis, manic arousal in patients with manic-depressive psychosis, mental disorders in patients with epilepsy, agitated depression in patients with presenile, manic-depressive psychoses, as well as other diseases accompanied by excitement, tension. Neurotic diseases, accompanied by an increase in muscle tone. Persistent pain, including causalgia (in combination with analgesics), persistent sleep disturbances (in combination with hypnotics and tranquilizers). Meniere’s disease, vomiting in pregnancy, treatment and prevention of vomiting in the treatment of anticancer drugs and radiation therapy. Dermatous itching. As part of lytic mixtures in anesthesiology.
Contraindications
Increased individual sensitivity to chlorpromazine or other components of the drug. Damage to the liver (cirrhosis, hepatitis, hemolytic jaundice, cholelithiasis), kidneys (nephritis, acute pyelitis, amyloidosis of the kidneys, urolithiasis), diseases of the hematopoietic organs, progressive systemic diseases of the brain and spinal cord (slow neuroinfections, multiple sclerosis), decompensated heart failure , severe cardiovascular diseases, gastric and duodenal ulcers during an exacerbation, decompensated heart defects, severe arterial hypotension, stroke, thromboembolic disease, severe myocardial dystrophy, rheumatic heart disease in the late stages, myxedema, late stage of bronchiectasis, glaucoma; urinary retention due to prostatic hyperplasia; severe depression of the central nervous system, coma, brain injury, acute infectious diseases. Do not use simultaneously with barbiturates, alcohol, drugs.
Directions
Aminazin (chlorpromazine) solution is administered intramuscularly or intravenously. The doctor sets the doses and treatment regimens individually, depending on the indications and the patient’s condition. With intramuscular injection, the highest single dose is 150 mg, daily – 600 mg. Usually, 1-5 ml of the solution should be injected intramuscularly no more than 3 times a day. The course of treatment – several months, in high doses – up to 1.5 months, then switch to treatment with maintenance doses, gradually reducing the dose by 25-75 mg per day. In case of acute mental agitation, administer intramuscularly 100-150 mg (4-6 ml of solution) or intravenously 25-50 mg (1-2 ml of chlorpromazine solution diluted in 20 ml of 5% or 40% glucose solution), if necessary, 100 mg (4 ml of solution – in 40 ml of glucose solution). Enter slowly. With intravenous administration, the highest single dose is 100 mg, daily – 250 mg.
With intramuscular and intravenous administration to children from 1 year old, a single dose is
250-500 mcg / kg of body weight; children from 5 years old (body weight up to 23 kg) – 40 mg per day,
5-12 years old (body weight – 23-46 kg) – 75 mg per day.
For debilitated and elderly patients, prescribe up to 300 mg per day intramuscularly or up to 150 mg per day intravenously.
Recent Reviews